(Reuters) - Columbia Laboratories' and Watson Pharmaceuticals' gel for reducing the risk of premature birth did not work for U.S. women, U.S. health reviewers said on Tuesday, sending shares of the companies tumbling. The Food and Drug Administration reviewers said the gel's efficacy was "a major concern" and asked an advisory panel to consider whether the company should conduct more U.S. clinical trials. Columbia's shares plunged more than 50 percent, while shares of Watson Pharmaceuticals, which is developing the drug with Columbia, dropped almost 7 percent. ... read more..
Joint Replacement Patients Face Blood Clot Risk in Hospital
TUESDAY, Jan. 17 (HealthDay News) -- One of every 100 people undergoing knee replacement surgery and 1 of 200 people having hip replacement surgery will develop a blood clot before they leave the hospital, even if they take steps to prevent the development of these blood clots, a new evidence review suggests. read more..
